Purpose: Osimertinib has proven efficacy in EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) patients; however, its benefits have not been evaluated in a real-world setting.
Methods: ASTRIS is a single-arm, open-label, multinational study to evaluate the efficacy and safety of osimertinib for the treatment of EGFR T790M mutation-positive NSCLC. We present the study design and preliminary cut-off analysis results (as of October 2017) describing the baseline characteristics and methodology for T790M mutation detection in the Spanish cohort.
Results: The Spanish cohort included 131 patients from a total 3014 patients. Forty patients (28.1%) were still undergoing therapy at the time of cut-off; 68.7% were women and 97.7% were Caucasian, with a mean age of 64.8 (SD 11.7) years. The most common type of sample for evaluating T790M mutations was tissue (55.0%), and samples were obtained from the primary tumor in 61.1% of cases. Mutation analysis was performed by the local laboratory in 60.3% of cases and using the Roche Cobas® EGFR assay in 43.5% of cases.
Conclusions: ASTRIS is expected to confirm the benefits of osimertinib in a real-world setting. Data on real-world practices for the detection of the EGFR T790M mutation may provide additional information for the designing of guidelines for best practices.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.patol.2019.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.
Jpn J Clin Oncol
December 2024
Department of Chemotherapy, Japan Red Cross Medical Center, 4-1-22, Hiroo, Shibuya-ku, Tokyo 150-8935, Japan.
Introduction: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including both sensitizing and T790M resistance mutations. Its real-world efficacy against uncommon EGFR mutations remains under-researched.
Methods: The REIWA study, a multicentric, prospective, observational study conducted in Japan from September 2018 to August 2020, enrolled patients with advanced or recurrent EGFR mutation-positive NSCLC receiving osimertinib.
Acquired multiple mutations‑mediated resistance to a third‑generation tyrosine kinase inhibitor in a patient with lung adenocarcinoma who responded to afatinib: A case report and literature review.
Oncol Lett
February 2025
Department of Thoracic Surgery, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong 518020, P.R. China.
For patients with advanced non-small cell lung cancer (NSCLC) that have epidermal growth factor receptor () mutations, EGFR tyrosine kinase inhibitors (TKIs) are the standard treatment and have significant clinical benefits. Third-generation TKIs, such as osimertinib, almonertinib and furmonertinib, are effective for the treatment of NSCLC that is EGFR-sensitizing mutation-positive and T790M-positive. Despite the efficacy of third-generation TKIs, patients inevitably develop resistance and the resistance mechanisms are heterogeneous.
View Article and Find Full Text PDF[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents].
Gan To Kagaku Ryoho
October 2024
Division of Medical Oncology, Dept. of Internal Medicine, Teikyo University School of Medicine.
Article Synopsis
- EGFR-TKIs are crucial for treating advanced non-small-cell lung cancer with EGFR gene mutations, with five variants approved in Japan, including gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib.
- Osimertinib is the only EGFR-TKI approved for second-line therapy in patients with the T790M mutation after initial treatment, making it essential to choose the right first-line therapy carefully.
- The article presents clinical data on EGFR-TKIs for first and second-line treatments, highlights the importance of patient and mutation subtype considerations, and shares experiences from transitioning between these therapies.
Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study.
Drugs Real World Outcomes
December 2024
Department of Internal Medicine, Toho University Sakura Medical Center, 564-1 Shimoshidu, Sakura-shi, Chiba, 285-8741, Japan.
Background: The prognosis of patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer has improved significantly since the advent of EGFR tyrosine kinase inhibitors (EGFR-TKIs). We aimed to investigate the relationship between patient characteristics, EGFR genotype, therapeutic agents, and the prognosis of the patients with EGFR mutation-positive lung cancer.
Methods: This retrospective cohort study analyzed 198 Japanese patients with unresectable EGFR mutation-positive lung cancer who were treated with EGFR-TKIs at Toho University Sakura Medical Center from April 2006 to December 2021.
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
Lung Cancer
September 2024
Betta Pharmaceuticals Co., Ltd, Hangzhou, China.
Article Synopsis
- The study analyzed the effectiveness of befotertinib, a drug for treating non-small cell lung cancer with EGFR T790M mutation, showing positive outcomes in patients with brain metastases and a manageable safety profile.
- Two groups of patients received different doses of the drug, and after tracking their progress for nearly four years, the overall survival rates were reported as 23.9 months and 31.5 months for the lower and higher doses, respectively.
- The results suggest that befotertinib offers significant overall survival benefits compared to other third-generation treatments, with adverse effects mostly manageable and in line with previous findings for similar cancer types.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!